Aprea Therapeutics to Host Pre-ESMO Virtual Panel on the State of WEE1 Inhibition in Precision Oncology

Aprea Therapeutics will host a virtual panel, "The State of WEE1 Inhibition in Precision Oncology," on October 20, 2026, at 11 am ET, ahead of the ESMO Congress 2026. The panel covers WEE1 biology, selectivity challenges in the drug class, and what to watch scientifically and in the market; it features oncologist Dr. Alex Spira, analyst Kevin DeGeeter of Ladenburg Thalmann, and Aprea's Chief Medical Advisor Dr. Eugene Kennedy.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.